Products
Amtabafusp Biosimilar Antibody Fusion Protein (CD3) for Research
Cat No.: GMP-Bios-INN-1075
Anti-CD3E therapeutic antibody (Pre-made Amtabafusp biosimilar,Whole mAb Fusion) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Amtabafusp (development code GS-8588) is a bispecific antibody fusion protein targeting CD3 and the HIV envelope protein gp120. It is developed by Gilead Sciences as a T-cell engager designed to eliminate HIV-infected cells. Further development details are under investigation.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1075-1mg | 1mg | 3090 |
| GMP-Bios-INN-1075-10mg | 10mg | |
| GMP-Bios-INN-1075-100mg | 100mg | |
| GMP-Bios-INN-1075-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Amtabafusp biosimilar, Whole mAb Fusion, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
| INN Name | Amtabafusp |
| Target | CD3E |
| Format | Whole mAb Fusion |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | TBC |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Production | na |
| Development Tech | TBC |
